PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.92%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-9.52%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-17.63%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-17.63%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-4.84%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-2.13%
Negative EPS growth while ADI is at 2.50%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
-2.52%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-2.41%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
29.35%
Dividend growth above 1.5x ADI's 2.21%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
101.67%
OCF growth at 75-90% of ADI's 125.40%. Bill Ackman would demand better working capital management or cost discipline.
341.26%
FCF growth 1.25-1.5x ADI's 250.94%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
204.26%
Similar 10Y revenue/share CAGR to ADI's 192.95%. Walter Schloss might see both firms benefiting from the same long-term demand.
111.21%
5Y revenue/share CAGR above 1.5x ADI's 63.20%. David Dodd would look for consistent product or market expansions fueling outperformance.
120.70%
3Y revenue/share CAGR above 1.5x ADI's 26.95%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
37.20%
10Y OCF/share CAGR under 50% of ADI's 386.27%. Michael Burry would worry about a persistent underperformance in cash creation.
18.07%
5Y OCF/share CAGR at 75-90% of ADI's 22.17%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
39.81%
3Y OCF/share CAGR at 50-75% of ADI's 74.89%. Martin Whitman would suspect weaker recent execution or product competitiveness.
2571.27%
Net income/share CAGR above 1.5x ADI's 335.80% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
727.64%
5Y net income/share CAGR 1.25-1.5x ADI's 513.24%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
129.87%
3Y net income/share CAGR above 1.5x ADI's 72.73%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
187.22%
Below 50% of ADI's 451.65%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
4.23%
Below 50% of ADI's 29.57%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
69.04%
3Y equity/share CAGR above 1.5x ADI's 14.78%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
87.75%
Dividend/share CAGR of 87.75% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
75.60%
Dividend/share CAGR of 75.60% while ADI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
184.42%
3Y dividend/share CAGR of 184.42% while ADI is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-15.08%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-3.62%
Inventory is declining while ADI stands at 0.32%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-5.78%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-3.10%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-2.46%
Our R&D shrinks while ADI invests at 1.09%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.39%
We cut SG&A while ADI invests at 1.05%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.